Simvastatin attenuates leucocyte–endothelial interactions after coronary revascularisation with cardiopulmonary bypass

M Chello, P Mastroroberto, G Patti, A D’Ambrosio, M Cortez Morichetti, G Di Sciascio, E Covino

Objective: To investigate the effects of preoperative simvastatin treatment on leucocyte–endothelial interactions following coronary artery bypass surgery with cardiopulmonary bypass.

Design: Double blind crossover study. Experiments on polymorphonuclear cells (neutrophils) were done at the end of cardiopulmonary bypass and one hour postoperatively. Endothelial P-selectin expression and neutrophil/endothelial adhesion were evaluated under either normoxic or hypoxic conditions.

Setting: University hospital (tertiary referral centre).

Patients: Three groups of patients undergoing coronary bypass surgery: 20 patients taking simvastatin for cholesterol control, 16 patients not responsive to simvastatin, and 20 controls.

Main outcome measures: Expression of neutrophil CD11b and endothelial P-selectin; adhesion of neutrophils to endothelium.

Results: Cardiopulmonary bypass resulted in a significant increase in neutrophil CD11b expression in all groups. Similarly, the exposure of saphenous vein to hypoxia/reoxygenation induced an augmentation of endothelial P-selectin. However, both neutrophil CD11b expression and endothelial P-selectin exocytosis were less in the simvastatin groups than in the controls. Cardiopulmonary bypass and controlled hypoxia/reoxygenation stimulated neutrophil/endothelial adhesion, but the number of adhering cells was less in the simvastatin groups than in the controls, irrespective of the cholesterol concentration. Treatment of endothelial cells with L-NAME completely reversed the effects of simvastatin.

Conclusions: Pretreatment with simvastatin reduces neutrophil adhesion to the venous endothelium in patients undergoing coronary surgery, irrespective of its efficacy at lowering cholesterol concentration.

Coronary endothelial dysfunction has been widely reported after coronary artery bypass surgery with cardiopulmonary bypass, and various factors have been identified as potential determinants. First, cardiopulmonary bypass itself is characterised by an inflammatory response in which the activated polymorphonuclear leucocytes (neutrophils) play an important role, mediating coronary and pulmonary endothelial injury by both capillary plugging of the myocardial microvasculature and release of reactive oxygen species, inflammatory cytokines, and proteolytic enzymes. Many of these substances in turn also mediate vascular endothelial dysfunction, characterised by loss of the ability of the endothelium to synthesise and release nitric oxide (NO).

Furthermore, hypothermic cardioplegic arrest exposes the coronary endothelium to a variable period of hypoxia/ischaemia, which stimulates P-selectin exocytosis on the coronary endothelial cell surface before reperfusion. The endothelium modulates the responsiveness of the underlying vascular smooth muscle mainly by the release of potent relaxing factors, one of which has been identified as NO, which is produced from L-arginine.

NO not only regulates vascular tone but has also been shown to play a significant role in leucocyte–endothelial interaction. The adhesion of neutrophils to the endothelium is directly mediated by specific “adhesion” molecules on the neutrophil and endothelial cell surfaces (selectins, integrins, and immunoglobulin superfamily members). NO has been shown to modulate leucocyte–endothelial cell interactions by suppressing the upregulation of several endothelial cell and neutrophil adhesion molecules, including P-selectin, VCAM-1, and CD11b/CD18.

Thus a reduced bioavailability of NO might cause progression and amplification of tissue injury, with neutrophil infiltration into inflamed tissues and local release of inflammatory mediators.

Besides the constitutive NO normally produced by endothelial cells, cardiopulmonary bypass has been shown to induce the release of an inducible form of NO (iNO), through the inducible enzyme NO synthase. Although constitutive NO appears to be cytoprotective and its release is impaired after cardiopulmonary bypass, several reports have highlighted the direct role of iNO in inducing myocardial and lung dysfunction through its negative inotropic effect, or by causing vasodilatation and increasing vascular permeability.

The 3-hydroxy 3-methyl-glutaryl coenzyme-A (HMG-CoA) reductase inhibitors, simply known as “statins”, are substances widely employed in the control of hypercholesterolaemia. The major mechanism of statins is the inhibition of cholesterol synthesis in the liver by blockade of HMG-CoA conversion to mevalonate, the rate limiting step in cholesterol biosynthesis. Clinical trials have shown that statins notably reduce cardiovascular morbidity and mortality in subjects with and without established coronary artery disease, and improve cardiovascular outcome after coronary artery bypass grafting. Nevertheless, from these studies it is evident that...
not all the clinical benefits of the agents can be explained by their lipid lowering effects, and a NO mediated anti-inflammatory action has been hypothesised. Pruefer and colleagues showed by intravital microscopy that the administration of simvastatin significantly inhibited leucocyte rolling, adherence, and transmigration in a rat model of the acute inflammatory state. This effect was found to be mediated by downregulation of P-selectin expression on endothelial cells, and is consistent with the downregulation of CD18 on stimulated neutrophils.

In the present study we tested the effects of simvastatin, at doses equivalent to those used orally for cholesterol control, on leucocyte-endothelial interactions in vitro during the inflammatory state following coronary artery bypass surgery with cardiopulmonary bypass.

METHODS

Among patients admitted for elective coronary artery bypass graft surgery (CABG) at the department of cardiac surgery at Catanzaro medical school, 56 who were taking simvastatin for treatment of hypercholesterolaemia were evaluated. Initiation of treatment with a lipid lowering agent was done at the discretion of the patient’s primary physician. A total cholesterol concentration > 6.2 mmol/l (> 240 mg/dl) was used to define hypercholesterolaemia. The patients had not taken any other cholesterol lowering drugs for at least a year. Diabetic patients, patients with renal or hepatic impairment, congestive heart failure, active inflammatory or immunomodulatory diseases, or a history of myocardial infarction less than six months previously, and pregnant women were excluded.

On admission, 36 subjects fulfilled the inclusion criteria and were included in the study. Among these patients, statin treatment was effective at lowering the cholesterol concentration in 20 (group A), and failed to produce therapeutic effects in 16 (group B). These patients were compared with 20 age and sex matched controls undergoing elective CABG who were normocholesterolaemic (group C).

Operative procedure

All patients underwent CABG with cardiopulmonary bypass using standard procedures. The surgical technique has been described in detail previously. The same standard anaesthesia protocol was used in all patients. After premedication, a Swan–Ganz catheter was positioned in the central pulmonary artery and a radial artery cannula was inserted. Cardioplectic arrest was achieved with ice cold St Thomas’ Hospital solution infused into the ascending aorta.

Study protocol

Blood samples were taken from the radial artery catheter before the induction of anaesthesia, at the end of cardiopulmonary bypass, and 60 minutes postoperatively. The samples were collected in cooled heparinised syringes which were immediately capped and stored in ice until separation and analysis. The study protocol was approved by the ethics committee of Catanzaro medical school. Informed consent was obtained from each patient.

Saphenous vein segment harvesting and culture

Segments of saphenous vein harvested at the time of bypass surgery were opened carefully and placed endothelial side up in separate 5 ml round cell culture dishes containing 3 ml of Krebs–Henseleit (K-H) solution, as described by Ma and colleagues. Experiments were done by placing the cell dishes in an acrylic chamber which provided a controlled temperature (37°C) and an atmosphere with the indicated amount of carbon dioxide (5%), the balance being made up of nitrogen. For the hypoxia–reoxygenation experiments, the vein segments were exposed to N₂:CO₂ (95:5) for 50 minutes followed by reoxygenation (21% O₂, 5% CO₂, 74% N₂) for two hours at 37°C.

Control vein segments were exposed to normoxia (21% O₂, 5% CO₂, 74% N₂) for the duration of the experiment (normoxic controls).

Neutrophil isolation

Neutrophils were isolated by Ficoll-Hypaque density gradient centrifugation, dextran sedimentation, and hypotonic lysis of erythrocytes. They were suspended in Hanks’ balanced salt solution, free from phenol red, Ca²⁺, and Mg²⁺, and containing 0.25% bovine serum albumin. The final cell preparation had 98 (2%) neutrophils (mean (SD)). The neutrophils were maintained on ice in Hanks’ balanced salt solution at 1 to 5x10⁶ cells/ml until used. Isolated neutrophils were more than 99% pure, as assessed by Wright’s stained cyt centrifuge preparation, and more than 99% viable, as assessed by exclusion of trypan blue.

Neutrophil CD11b expression

Neutrophil CD11b expression was detected by indirect immunofluorescence and flow cytometry as previously described. In brief, 1 ml of blood was drawn from the oxygenator into a heparinised syringe which was kept at room temperature to minimise the effects of cooling and rewarming on neutrophil integrin expression. Samples of blood in aliquots of 100 µl were put in polypropylene tubes and stained with anti-CD11b monoclonal antibody CBL145 (Cymbus Biosciences, Hampshire, UK) as the primary reagent, and fluorescein isothiocyanate conjugated goat anti-mouse immunoglobulin (Cymbus Biosciences) as the secondary reagent. Flow cytometry was done on a FACScan (Becton Dickinson, Mountain View, California, USA). In the flow cytometry studies, the logarithmic mean fluorescence values obtained from the histograms were converted mathematically into a relative fluorescence value and expressed as per cent increase over the observed baseline values.

Immunohistochemistry

Immunostaining was used to investigate the extent of P-selectin expression in saphenous vein segments. Saphenous vein was dehydrated using graded acetone washes and embedded at 4°C. Sections 6 µm thick were cut and transferred to coated slides ( Vectabond; Vector Laboratories, Burlington, California, USA). The immunohistochemical localisation of P-selectin was accomplished using the avidin-biotin immunoperoxidase technique, as described by Chester and colleagues. Tissue sections were incubated with the primary antibody (Research Diagnostic, Flanders, New Jersey, USA, at 1:100 dilution) overnight at room temperature. A biotinylated IgG was used as the secondary antibody at a 1:200 dilution. In brief, 1 ml of blood was drawn from the oxygenator into a heparinised syringe which was kept at room temperature to minimise the effects of cooling and rewarming on neutrophil integrin expression. Samples of blood in aliquots of 100 µl were put in polypropylene tubes and stained with anti-CD11b monoclonal antibody CBL145 (Cymbus Biosciences, Hampshire, UK) as the primary reagent, and fluorescein isothiocyanate conjugated goat anti-mouse immunoglobulin (Cymbus Biosciences) as the secondary reagent. Flow cytometry was done on a FACScan (Becton Dickinson, Mountain View, California, USA). In the flow cytometry studies, the logarithmic mean fluorescence values obtained from the histograms were converted mathematically into a relative fluorescence value and expressed as per cent increase over the observed baseline values.

Neutrophil adherence assay

Neutrophils were fluorescently labelled with a hydrophobic fluorescent compound 3-3′- diiodoacetoxycarbocyanine perchorlate (DiI) (Fluka, Sigma-Aldrich, Milan, Italy), as previously described. Cells at a concentration of 4 to 8 x 10⁶ cells/ml were incubated with 50 µg/ml DiI in HAP buffer for 10 minutes at 0°C, unbound dye was removed by three washes with HAP buffer, and labelled neutrophils were resuspended in medium. Adhesion assay. After 10 minutes of preincubation of the vessel segments, autologous unstimulated DiI labelled neutrophils (10 µl of 10⁶ cells/ml) were added and incubated for 20 minutes. Vessel segments were
then removed from culture dishes and dipped three or four times in fresh K-H solution. These vessel segments were then placed on a glass slide with the endothelial side up. The number of neutrophils adhering to the endothelial surface in five separate microscopic fields was counted manually on an inverted microscope equipped for fluorescence, using the filter IF355–550. Values of five replicates were averaged, and variations between replicates were < 10%.

**Inhibition of NO release from saphenous vein endothelial cells**

We observed the effect of inhibiting basal NO release from the saphenous vein on neutrophil adherence to endothelium. NG-nitro-L-arginine methyl ester (L-NAME, 1 mmol/l) was incubated with vessel segments for 30 minutes. These vessel segments were then transferred to fresh K-H solution that did not contain L-NAME. Stimulated autologous neutrophils were then incubated for another 20 minutes with these vessel segments. Neutrophil adhesion to the endothelium was evaluated as described earlier. In other experiments, the L-NAME vessel segments were coincubated with L-arginine (10⁻⁷ mol/l) or nitroprusside (1 mmol/l) to determine whether substrate or exogenous NO inhibited neutrophil adhesion to L-NAME treated vascular segments.

In a subset of experiments (10 for each group), the importance of neutrophil CD11b and endothelium P-selectin in determining neutrophil/endothelial adhesion was evaluated by treating neutrophils and saphenous vein endothelium with blocking monoclonal antibodies (mAb) to CD11b and P-selectin.

**Statistics**

Data are presented as mean (SEM). Raw data were analysed for normality of distribution. If not normally distributed, data were subjected to log transformation before analysis. We used χ² tests to compare categorical variables or non-paired Student's t tests as appropriate. Comparison between groups was made by using two way analysis of variance with the Bonferroni correction for t test comparison. A probability value of p < 0.05 was considered significant.

**RESULTS**

**Patients**

Clinical and operative characteristics (shown in table 1) did not differ between the three groups. All patients had angina on effort and were receiving some combination of β adrenergic blocking agents, nitrate vasodilators, and calcium channel blocking agents.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Group A</th>
<th>Group B</th>
<th>Group C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>53.4 (3.1)</td>
<td>55 (2.5)</td>
<td>52.2 (3.3)</td>
</tr>
<tr>
<td>NYHA class</td>
<td>2.2 (0.1)</td>
<td>2.3 (0.3)</td>
<td>2.1 (0.7)</td>
</tr>
<tr>
<td>Additional drugs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>β-blockers</td>
<td>8</td>
<td>6</td>
<td>9</td>
</tr>
<tr>
<td>Calcium channel blockers</td>
<td>13</td>
<td>11</td>
<td>15</td>
</tr>
<tr>
<td>Nitrates</td>
<td>16</td>
<td>13</td>
<td>15</td>
</tr>
<tr>
<td>Total CPB time (min)</td>
<td>96 (7.7)</td>
<td>103 (6.5)</td>
<td>101 (9.2)</td>
</tr>
<tr>
<td>Aortic cross clamp (min)</td>
<td>48 (5.4)</td>
<td>52 (4.8)</td>
<td>46 (6)</td>
</tr>
<tr>
<td>Number of grafts</td>
<td>2.2 (0.3)</td>
<td>2.3 (0.2)</td>
<td>2.2 (0.4)</td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>5.11 (0.16)</td>
<td>6.94 (0.17)</td>
<td>4.44 (0.20)</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/l)</td>
<td>1.50 (0.09)</td>
<td>1.30 (0.11)</td>
<td>1.14 (0.11)</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>1.93 (0.14)</td>
<td>2.01 (0.21)</td>
<td>1.89 (0.24)</td>
</tr>
</tbody>
</table>

Values are n or mean (SD).

Group A, hypercholesterolaemic, responsive to simvastatin; group B, hypercholesterolaemic, non-responsive to simvastatin; group C, control.

**Neutrophil CD18/CD11b expression**

Figure 1 shows neutrophil CD11b expression in control and simvastatin (S) treated patients. Values are expressed as a percentage of the baseline value (mean channel fluorescence: control, n = 83; simvastatin responsive, n = 79; simvastatin non-responsive, n = 81). In all patients, a significant increase in CD11b expression was observed throughout the experimental period, with a peak at 60 minutes postoperatively. However, at this latter point, CD11b values from patients treated with simvastatin were significantly lower than in the control group.

**P-selectin expression on saphenous vein endothelial cells**

In normoxic vessel segment from all groups, P-selectin staining was only weakly positive on the endothelial cells. We therefore investigated the effect of hypoxia (95% N₂, 5% CO₂) and reoxygenation (95% air, 5% CO₂) on the expression of P-selectin by saphenous vein endothelial cells. Figure 2 summarises the results and shows that, compared with normoxia, a period of hypoxia similar to that induced in the coronary endothelium...
Figure 2  P-selectin expression of saphenous vein endothelium exposed to normoxia (O2 21%) or 50 minutes of hypoxia (H/R, N2:CO2, 95:5). The bars represent the mean number of positive staining vein segments/examined area. **p < 0.01 v control.

by aortic cross clamping resulted in a highly significant increase in endothelial P-selectin expression in vein segments from all groups (control: p < 0.01 v normoxia, mean difference −8.9, 95% confidence interval (CI) −11.5 to −6.3; simvastatin responsive: p < 0.01 v normoxia, mean difference −4.3, 95% CI −6.9 to −1.8; simvastatin non-responsive: p < 0.01 v normoxia, mean difference −5.0, 95% CI −7.9 to −2.1). P-selectin expression was significantly reduced in vessel segments after simvastatin treatment, independently of its efficacy at lowering cholesterol (simvastatin responsive: p < 0.01 v control, mean 4.8, 95% CI 2.3 to 7.4; simvastatin non-responsive: p < 0.01, mean 3.8, 95% CI 1.2 to 6.3).

Neutrophil adhesion to saphenous vein endothelial cells

Figure 3 shows the percentage of neutrophil adhesion to the endothelium of saphenous vein segments. Under baseline condition very few neutrophils bound to endothelium, and no significant difference was observed between the three groups. In contrast, in experiments with neutrophils obtained one hour postoperatively, adhesion and ruffle formation of neutrophils on normoxic endothelium were notably enhanced. However, on the basis of counts made before and after washing, the percentage of neutrophils adhering to the saphenous vein endothelium was significantly lower in the statin groups than in the control group (simvastatin responsive: p < 0.01 v control, mean difference 7.5%, 95% CI 4.0 to 11.1; simvastatin non-responsive: p < 0.01 v control, mean difference 6.7%, 95% CI 3.2 to 10.3). When the neutrophils were incubated with vein segments after hypoxia/reoxygenation, a greater number of adhering neutrophils was found compared with the normoxic vein segments. Again, the percentage of neutrophils adhering to the endothelium was significantly lower in the statin groups than in the control group (simvastatin responsive: p < 0.01 v control, mean difference 8.4%, 95% CI 4.9 to 12.0; simvastatin non-responsive: p < 0.01, mean difference 9.2%, 95% CI 5.7 to 12.8).

Figure 4 shows the results of a subset of experiments using hypoxic vein segments (n = 10), in which neutrophils obtained 60 minutes postoperatively were incubated with a blocking CD11b antibody (clone 44a). The incubation of neutrophils with mAb 44a caused a decrease in neutrophil adhesion of 50%, 40%, and 42% in the control, simvastatin responsive, and simvastatin non-responsive groups, respectively. The contribution of P-selectin to ischaemia/reoxygenation-enhanced adherence was determined by comparing exposing saphenous vein segments to a 1:200 dilution of blocking P-selectin mAb 9E1. Figure 4 shows that incubation of the ischaemic/reoxygenated vein segment with mAb 9E1 further reduced the adhesion of mAb44 treated neutrophil to the vein endothelium (by 80%, 70%, and 68% in control, simvastatin responsive, and simvastatin non-responsive groups, respectively).

In an attempt to relate the simvastatin modulation of neutrophil adherence to saphenous vein endothelium with enhanced basal NO production, we studied the effects of L-NAME added directly to the bath. Figure 4 summarises the results. Addition of L-NAME directly to the bath increased neutrophil adherence to the vein endothelium in the statin groups (simvastatin responsive: p < 0.05 v no L-NAME, mean difference −7.5, 95% CI −14.5 to −0.4; simvastatin non-responsive: p < 0.05 v no L-NAME, mean difference −7.6, 95% CI −15.0 to −0.2), with no significant difference observed between groups. Moreover, both the addition of L-arginine and supplementation of exogenous NO by nitroprusside significantly reduced the L-NAME induced neutrophil adhesion to vascular endothelium (data not shown). These results suggest that endogenous NO generated from vein endothelium acts as an inhibitor of neutrophil adherence.

DISCUSSION

Lipid lowering treatment with HMG-CoA reductase inhibitors has been shown to reduce cardiovascular morbidity and mortality in patients with and without cardiovascular disease. 16 27 28 31 Datani and colleagues 16 showed that preoperative statin treatment may be associated with a reduced incidence of post-CABG adverse cardiovascular outcomes. A
Reduced release of IL-6 during elective CABG after preoperative statin treatment has also been reported. Moreover, simvastatin treatment has been associated with improvement in coronary artery function together with decreased cytokine activation in patients after heart transplantation. Our results extend these conclusions and demonstrate that the benefits of statin treatment may also occur in the immediate postoperative period after CABG. In the present study, statin treatment was associated with lowered adhesion of activated neutrophils to vascular endothelium after hypoxia/reoxygenation, by a mechanism involving reduced expression of both neutrophil CD11b and endothelial P-selectin. These endothelial protective effects are independent of the well-known lipid lowering effects of statins, and occurred at clinically therapeutic doses in patients in whom statin treatment failed to lower the cholesterol concentrations. Our results are consistent with those of previous studies in which statins were found to inhibit both neutrophil activation and the process of P-selectin expression in the endothelial cell. In a recent publication, Florens and colleagues failed to show an anti-inflammatory effect of acute pretreatment with atorvastatin (40 mg the evening before and 40 mg on the morning of surgery). These differences in results could be explained by the acute setting of the study, with a time interval less than 24 hours between drug administration and the assay of the inflammatory response. In our study, treated patients had been on chronic treatment with statins for at least three months (median nine months, mean (SD) dose 26.4 (0.4) mg/day), and treatment of at least three months with statins was advocated in a previous study as being effective for improving the bioavailability of nitric oxide. The results of the present study confirm that cardiopulmonary bypass is associated with significant neutrophil activation, as evidenced by increased Mac1 expression. However, the most interesting observation was the significant attenuation of CD11b neutrophil upregulation following treatment with statins, which in turn is responsible for a reduced neutrophil adhesion to the endothelial cells in both normoxic and ischemic reperfusion experiments. Our findings are in agreement with those of Lefer and colleagues, who showed that simvastatin significantly inhibited the upregulation of CD11b expression on stimulated rat neutrophils by a mechanism not involving its cholesterol lowering effects. A similar effect has been described by Weber and associates for lovastatin, which decreases CD11b expression and CD11b dependent adhesion of monocytes to the endothelium in humans, independent of any cholesterol lowering effects. The importance of surface CD11b in mediating neutrophil–endothelial adhesion has been demonstrated before. In the present study, pretreatment with anti-Mac1 blocking antibodies significantly reduced neutrophil/endothelial adhesion in hypoxic experiments, although the number of neutrophils adhering to the endothelium was still increased, with higher values in control groups than in statin groups. This latter finding might certainly be explained by the increased expression of adhesion molecule P-selectin on the endothelial cell surface after hypoxia/reoxygenation, which would account for the rolling and the early adhesion of neutrophils. In fact, incubation of endothelial cell with monoclonal blocking antibodies against P-selectin almost completely abolished neutrophil adhesion.
P-selectin is an endothelial adhesion molecule found constitutively in a preformed state in the α granules of platelets and in the Weibel–Palade bodies of endothelial cells. It is rapidly translocated to the cell surface after stimulation with inflammatory mediators, allowing rolling and adhesion of activated neutrophils to the endothelium. This latter phenomenon is crucial in mediating leukocyte adhesion to platelets and endothelium after ischaemia/reoxygenation. Pinsky and colleagues demonstrated P-selectin exocytosis on coronary endothelial cells of patients undergoing routine cardiac surgery under hypothermic cardiopulmonary arrest. In our study, we confirmed the observation that a relatively brief period of hypoxia followed by reoxygenation elicits a significant increase in P-selectin at the endothelial surface of saphenous vein. However, vein segments from a patient under statin treatment expressed significantly less P-selectin on the endothelial surface after 50 minutes of hypoxia followed by reperfusion, with a beneficial effect on leukocyte–endothelial interactions compared with controls. This effect was not related to the cholesterol lowering effect of simvastatin, as it was also manifested in group B patients who did not benefit from simvastatin treatment in terms of reduced cholesterol. Our results are in agreement with those of Pruefer and colleagues, who showed a significant attenuation in the upregulation of P-selectin on the mesenteric endothelium in an acute inflammatory state after treatment with simvastatin. In conclusion, in experiments using either blood vessels or neutrophils isolated from statin treated patients, adherence was significantly attenuated. Thus simvastatin exerts an anti-adherence effect acting both on neutrophils and on the endothelium.

**Statin treatment improves endothelial function after ischaemia/reperfusion**

Endothelial dysfunction has long been shown to be a critical early component of organ injury following myocardial ischaemia and reperfusion during coronary surgery under cardiopulmonary bypass, and has led to the investigation of strategies to prevent its occurrence. Moreover, cardiopulmonary bypass itself causes local injury secondary to an acute inflammatory response that involves tissue infiltration by activated neutrophils and platelets. The mechanism of endothelial dysfunction and reduced NO bioavailability in ischaemia/reperfusion injury is still being debated. Data from studies in animals suggest that there might either be reduced substrate for NO synthesis or increased NO inactivation by neutrophil released superoxide. Recent results suggest that the cardioprotective effects of statins can be at least partially explained by the enhancement of endothelial NO synthase (eNOS) expression, which therefore overcomes the hypoxia mediated inhibition of NO synthesis activity. Laufs and colleagues have shown that simvastatin and lovastatin improve the stability of the mRNA for eNOS and increase the half-life of the mRNA for eNOS from 13 to 38 hours, with a consequent enhanced generation of NO from the endothelium. Wassmann and colleagues showed that 30 days of treatment with atorvastatin in normocholesterolaemic, spontaneously hypertensive rats caused an upregulation of eNOS mRNA expression (138 (71)% of control) and an enhanced eNOS activity in the vessel wall (209 (46)% of control). Moreover, treatment with atorvastatin caused a significant reduction in systolic blood pressure and a profound improvement in endothelial dysfunction mediated by a reduction in free radical release in the vasculature. Upregulation of endothelial NO synthesis, as well as inhibition of hypoxia mediated inhibition of NOS activity, has been observed with simvastatin and lovastatin in mice subjected to cerebral ischaemia–reperfusion. These effects were dependent on enhanced NO formation because they failed to ameliorate the high leukocyte rolling and adherence in eNOS deficient mice.

The results of the present study are in accordance with these past reports and show that the downregulation of both P-selectin expression on endothelial cells and CD18 on stimulated neutrophils is mediated by enhanced NO synthesis. In our experiments, the addition of L-NAME, an inhibitor of NO
synthase, in the culture media of vein segments almost completely abolished the statin effect on endothelial–endothelial adhesion. In the same fashion, when L-NAME was added to neutrophils withdrawn at the end of cardiopulmonary bypass, the number of neutrophils adhering to non-stimulated endothelial cells did not differ between the control group and the treatment groups.

Limitations of the study
In our study, we tested neutrophil–endothelial adhesion by using segments of saphenous vein subjected to a brief period of controlled hypoxia/reoxygenation. In the clinical setting of coronary artery bypass, ischaemia/reperfusion injury mainly involves the coronary endothelium, in which the Po2 declines to < 20 torr. Nevertheless, we can only speculate that the observation made with a saphenous vein model could be extrapolated to the coronary endothelium. Furthermore, ischaemia/reperfusion is not the only cause of the endothelial dysfunction which occurs during cardiopulmonary bypass. After operation there are several potential stimuli for the expression of adhesion molecules in veins. These include the action of the cytokines released as a result of cardiopulmonary bypass, and increased stretch in the vessel wall because of mechanical distension and exposure to arterial pressure. In the controlled setting of our experiment, we could not consider the influence on the endothelial cells of cytokine action, neutrophils themselves.

Conclusions
Although further studies are advisable to clarify the exact mechanism of action, we can affirm on the basis of our data that pretreatment with simvastatin significantly reduces neutrophil adhesion to the venous endothelium, by an NO mediated mechanism, in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass, irrespective of its efficacy at lowering cholesterol concentrations.

Authors’ affiliations
M Chello, G Patti, A D’Ambrosio, M Cortez Morichetti, G Di Sciascio, E Cozzolino. Interdisciplinary Centre for Biomedical Research (CIR), Department of Cardiovascular Sciences, University Campus Bio-Medico di Roma, Rome, Italy
E Mastroroberto, Department of Clinical and Experimental Medicine, University of Catanzaro, Catanzaro, Italy

REFERENCES

Simvastatin attenuates leucocyte–endothelial interactions after coronary revascularisation with cardiopulmonary bypass

M Chello, P Mastroroberto, G Patti, A D'Ambrosio, M Cortez Morichetti, G Di Sciascio and E Covino

Heart 2003 89: 538-543
doi: 10.1136/heart.89.5.538

Updated information and services can be found at:
http://heart.bmj.com/content/89/5/538

These include:

References

This article cites 38 articles, 14 of which you can access for free at:
http://heart.bmj.com/content/89/5/538#BIBL

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

Interventional cardiology (2933)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/